-
Eli Lilly and Novo Nordisk Ramp Up Production Capacity to Meet Surging Global Demand for Groundbreak...
In the global pharmaceutical market, especially in the field of treatment for diabetes and obesity, GLP-1 (glucagon-like peptide-1) drugs are becoming...
2024-06-28 17:37 -
Eli Lilly's Zepbound (Tizepatide) Demonstrates Promising Results in Treating Obesity and Obstructive...
In the era of rapid advancement in medical technology, obesity and its related complications are becoming a global public health challenge.
2024-06-28 17:35 -
AbbVie's Persistent Pursuit of a Revolutionary Parkinson's Treatment: Navigating FDA Challenges and ...
After being rejected by the US Food and Drug Administration (FDA) over a year ago, the world's leading biopharmaceutical company AbbVie did not give u...
2024-06-28 17:34 -
Pfizer's Resurgence in the RSV Vaccine Market: Reclaiming Ground and Intensifying Global Competition
After temporarily losing out to GSK in the race for an RSV vaccine with Pfizer choosing not to stand still, the company has instead regrouped and is p...
2024-06-28 17:31 -
Scrutinizing the Pricing of Diabetes Drug Ozempic: A Call for Fairness and Transparency
In a recent and impactful tweet, U.S. Senator Bernie Sanders (I-Vt.) has harshly criticized the pricing strategy of the highly-watched diabetes drug O...
2024-06-28 17:22 -
Charles River's Strategic Investments and Financial Performance
Charles River has implemented a series of investment strategies, including acquisitions, technology partnerships, and internal development, to gain ac...
2024-06-28 09:55 -
Bayer's Novel Drugs for Late-Stage Solid Tumors and Acute Ischemic Stroke Receive Clinical Trial App...
BAY 2862789 oral solution, a small-molecule DGKα inhibitor co-developed by Bayer and the German Cancer Research Center (DKFZ), is now undergoing the ...
2024-06-27 18:48 -
SINOPEP's Success in the Peptide Drug Market
SINOPEP's main source of revenue is its series of products, namely active pharmaceutical ingredients (APIs).
2024-06-27 18:44 -
Harbour BioMed Resubmits Biologics License Application for Batoclimab (HBM9161) for the Treatment of...
Batoclimab (HBM9161), as a fully human monoclonal antibody, works by blocking the interaction between FcRn and IgG, thereby accelerating the clearance...
2024-06-27 18:42 -
Amylyx Acquires Avexitide from Eiger, Aims to Expand in Insulin-Related Diseases
According to official documents released by the U.S. Securities and Exchange Commission (SEC), the pharmaceutical company Amylyx, headquartered in Cam...
2024-06-27 18:27
Hot News
- German Chemical Industry Outpu... Sep 15, 2025
- BASF’s Big Restructuring: Cut... Sep 01, 2025
- DuPont Bids Farewell to Its Ar... Sep 02, 2025
- ExxonMobil Eyes $1 Billion Pet... Sep 16, 2025
- FDA Clears Sanofi’s Wayrilz (... Aug 31, 2025
Related Products
Related Producers
